Sacubitril/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM).

Lazar VelickiDejana PopovicNduka C OkwoseAndrej PrevedenMilorad TesicMaria TafelmeierSarah J CharmanFausto BarloccoGuy A MacGowanPetar M SeferovicNenad FilipovicArsen RisticIacopo OlivottoLars S MaierDjordje G Jakovljevićnull null

Published in: European journal of heart failure (2024)

In patients with HCM, a 16-week treatment with sacubitril/valsartan was well tolerated but had no effect on exercise capacity, cardiac structure, or function.

Keyphrases

hypertrophic cardiomyopathy
randomized controlled trial
left ventricular
ejection fraction
systematic review
combination therapy
atrial fibrillation